IBID

iShares iBonds Oct 2027 Term TI

Bearish Trend

Near 52W High

$25.80+$0.01 (+0.04%)

Loading Chart...

Institutional Signal // Day Trade Edge:Neutral / No Active Setup Today

Scan Active Universe on Day Trade Edge

Key Statistics

Market Cap—

Forward P/E—

EPS (TTM)—

52-Week Return-1.74%

50-Day Moving Avg$25.82

200-Day Moving Avg$25.99

Volume Today51.09K

Avg Volume44.1K

Day Range$25.78 – $25.80

52-Week Range$25.63 – $26.39

Open Price$25.81

Previous Close$25.79

Company Profile

Description

The index consists of inflation-protected public obligations of the U.S. Treasury, commonly known as “TIPS,” that are scheduled to mature between January 1, 2027 and October 15, 2027, inclusive. The fund will invest at least 80% of its assets in the component securities of the underlying index.

SEC Filings

EDGAR Filings

Exchange Listing

Nasdaq.com

Company Profile

Description

SEC Filings

EDGAR Filings

Exchange Listing

Nasdaq.com

IBID

Key Statistics

Company Profile

Company Profile

Recent News

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

Radoff-JEC Group Calls on Seer, Inc.’s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers

Haleon and Singapore's Agency for Science, Technology and Research (A*STAR) Launch New Clinical Study on Women's Metabolic Health in Asia

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

Letter to the Shareholders of Workspace Group plc

Seer Board of Directors Issues Letter to Shareholders Highlighting the Company’s Significant Scientific Progress and Addressing Radoff and Torok’s Short-Sighted Campaign

The Radoff-JEC Group Highlights Seer Inc.’s and Chairman and CEO Omid Farokhzad, M.D.’s History of Value Destruction

Recent News

Company Profile

Recent News

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

Radoff-JEC Group Calls on Seer, Inc.’s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers

Haleon and Singapore's Agency for Science, Technology and Research (A*STAR) Launch New Clinical Study on Women's Metabolic Health in Asia

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

Letter to the Shareholders of Workspace Group plc

Seer Board of Directors Issues Letter to Shareholders Highlighting the Company’s Significant Scientific Progress and Addressing Radoff and Torok’s Short-Sighted Campaign

The Radoff-JEC Group Highlights Seer Inc.’s and Chairman and CEO Omid Farokhzad, M.D.’s History of Value Destruction